Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Study sponsor: Inhibikase Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-06-30Estimated
Enrollment · participants484Estimated
Source updated2026-06-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.